Scalable Hybrid Synthetic/Biocatalytic Route to Psilocybin
Chemistry - A European Journal February 26, 2020 Janis Fricke, Robert B. Kargbo, Lars Regestein et al. 48 citations
Abstract Psilocybin, the principal indole alkaloid of Psilocybe mushrooms, is currently undergoing clinical trials as a medication against treatment‐resistant depression and major depressive disorder. The psilocybin supply for pharmaceutical purposes is met by synthetic chemistry. We replaced the problematic phosphorylation step during synthesis with the mushroom kinase PsiK. This enzyme was...